204 related articles for article (PubMed ID: 35930804)
21. Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.
Scharpf RB; Balan A; Ricciuti B; Fiksel J; Cherry C; Wang C; Lenoue-Newton ML; Rizvi HA; White JR; Baras AS; Anaya J; Landon BV; Majcherska-Agrawal M; Ghanem P; Lee J; Raskin L; Park AS; Tu H; Hsu H; Arbour KC; Awad MM; Riely GJ; Lovly CM; Anagnostou V
Cancer Res; 2022 Nov; 82(21):4058-4078. PubMed ID: 36074020
[TBL] [Abstract][Full Text] [Related]
22. Targeting the ERβ/HER Oncogenic Network in
Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514
[TBL] [Abstract][Full Text] [Related]
23. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
[TBL] [Abstract][Full Text] [Related]
24. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya I; Roman M; Welch C; Entrialgo-Cadierno R; Salmon M; Santos A; Feliu I; Kovalski J; Lopez I; Rodriguez-Remirez M; Palomino-Echeverria S; Lonfgren SM; Ferrero M; Calabuig S; Ludwig IA; Lara-Astiaso D; Jantus-Lewintre E; Guruceaga E; Narayanan S; Ponz-Sarvise M; Pineda-Lucena A; Lecanda F; Ruggero D; Khatri P; Santamaria E; Fernandez-Irigoyen J; Ferrer I; Paz-Ares L; Drosten M; Barbacid M; Gil-Bazo I; Vicent S
Nat Commun; 2023 Oct; 14(1):6332. PubMed ID: 37816716
[TBL] [Abstract][Full Text] [Related]
25. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
26. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.
Lussier DM; Alspach E; Ward JP; Miceli AP; Runci D; White JM; Mpoy C; Arthur CD; Kohlmiller HN; Jacks T; Artyomov MN; Rogers BE; Schreiber RD
Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34099555
[TBL] [Abstract][Full Text] [Related]
27. Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.
Zhu M; Kim J; Deng Q; Ricciuti B; Alessi JV; Eglenen-Polat B; Bender ME; Huang HC; Kowash RR; Cuevas I; Bennett ZT; Gao J; Minna JD; Castrillon DH; Awad MM; Xu L; Akbay EA
Cancer Cell; 2023 Oct; 41(10):1731-1748.e8. PubMed ID: 37774698
[TBL] [Abstract][Full Text] [Related]
28. CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development.
Melese ES; Franks E; Cederberg RA; Harbourne BT; Shi R; Wadsworth BJ; Collier JL; Halvorsen EC; Johnson F; Luu J; Oh MH; Lam V; Krystal G; Hoover SB; Raffeld M; Simpson RM; Unni AM; Lam WL; Lam S; Abraham N; Bennewith KL; Lockwood WW
Oncoimmunology; 2022; 11(1):2010905. PubMed ID: 35481284
[TBL] [Abstract][Full Text] [Related]
29. KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.
Guibert N; Ilie M; Long E; Hofman V; Bouhlel L; Brest P; Mograbi B; Marquette CH; Didier A; Mazieres J; Hofman P
Curr Mol Med; 2015; 15(5):418-32. PubMed ID: 25941815
[TBL] [Abstract][Full Text] [Related]
30. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
31. Does Molecular Profiling of
Karim NA; Ullah A; Pathrose P; Fathallah H; Perry A; Morris JC; Wang J; Starnes SL
Curr Oncol; 2022 Jul; 29(7):4779-4790. PubMed ID: 35877239
[TBL] [Abstract][Full Text] [Related]
32. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242
[TBL] [Abstract][Full Text] [Related]
33. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
Salgia R; Pharaon R; Mambetsariev I; Nam A; Sattler M
Cell Rep Med; 2021 Jan; 2(1):100186. PubMed ID: 33521700
[TBL] [Abstract][Full Text] [Related]
34. KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.
Naidoo J; Drilon A
Adv Exp Med Biol; 2016; 893():155-178. PubMed ID: 26667343
[TBL] [Abstract][Full Text] [Related]
35. PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer.
Long LL; Ma SC; Guo ZQ; Zhang YP; Fan Z; Liu LJ; Liu L; Han DD; Leng MX; Wang J; Guo XJ; Tan JL; Cai XT; Lin Y; Pan X; Wu DH; Bai X; Dong ZY
Cancer Res; 2023 Feb; 83(4):568-581. PubMed ID: 36512628
[TBL] [Abstract][Full Text] [Related]
36. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
37. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.
Lee C; Jiang ZK; Planken S; Manzuk LK; Ortiz R; Hall M; Noorbehesht K; Ram S; Affolter T; Troche GE; Ihle NT; Johnson T; Ahn Y; Kraus M; Giddabasappa A
Mol Cancer Ther; 2023 Jul; 22(7):891-900. PubMed ID: 37186518
[TBL] [Abstract][Full Text] [Related]
39. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
